Summary
As part of the agreement, Hims said it won’t compound GLP-1 medications like Zepbound in the future.
Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.
Source & full coverage: this summary is aggregated from MarketWatch, the original publisher. Read the complete report for full context, data and quotes.
Read the original report at MarketWatch →
